title: Hope for disease-modifying treatment of systemic sclerosis/scleroderma.
authors: Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany; and Department of Translational Medicine and Clinical Pharmacokinetics, Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany marmiche@uni-mainz.de.
authors: Martin C
authors: MC
authors: Michel
mesh_terms: D000818:Animals; D004268:DNA-Binding Proteins / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D058628:Myofibroblasts / Q000187:drug effects*; D009557:Nipecotic Acids / Q000627:therapeutic use*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D026362:Serum Response Factor / Q000235:genetics*; D014158:Transcription, Genetic / Q000187:drug effects*
chemical_list: D004268:DNA-Binding Proteins; D009557:Nipecotic Acids; D015514:Oncogene Proteins, Fusion; D026362:Serum Response Factor